ASCO 2019 day two
Exclusive live coverage from day two of the American Society of Clinical Oncology’s annual meeting in Chicago.
• To view all of our coverage from the preeminent cancer event, produced in association with Kantar Health, as well as additional content, visit the Spotlight on ASCO 2019 and the future of oncology
Saturday at ASCO 2019 will see Gilead’s Kite unveil end of phase 1 data from ZUMA-3, a phase 1/2 study of the company’s investigational KTE-X19, an anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia.
Also on the agenda for Saturday:
- Five-year overall survival data from Keynote-001, for patients with advanced non-small cell lung cancer treated with Merck & Co’s PD-1 cancer immunotherapy Keytruda (pembrolizumab). Late breaking data will only cover data from non-small cell lung cancer from a group of patients with advanced carcinoma, melanoma, and NSCLC.
- Phase 2 data from an open-label study of Novartis’ PD-1 spartalizumab.
View the live coverage from day two at ASCO 2019 below (the live blog may take a few seconds to load) and we will also have live coverage from day three at ASCO: